Zoetis Inc (NYSE:ZTS) insider Roman Trawicki sold 8,568 shares of the business’s stock in a transaction that occurred on Friday, March 9th. The stock was sold at an average price of $83.10, for a total value of $712,000.80. Following the sale, the insider now directly owns 11,457 shares of the company’s stock, valued at $952,076.70. The sale was disclosed in a legal filing with the SEC, which is accessible through this link.
Roman Trawicki also recently made the following trade(s):
- On Friday, February 23rd, Roman Trawicki sold 23,885 shares of Zoetis stock. The stock was sold at an average price of $82.00, for a total value of $1,958,570.00.
Zoetis stock opened at $84.10 on Thursday. Zoetis Inc has a twelve month low of $52.25 and a twelve month high of $85.73. The firm has a market capitalization of $40,348.84, a price-to-earnings ratio of 48.06, a price-to-earnings-growth ratio of 1.87 and a beta of 0.97. The company has a current ratio of 3.85, a quick ratio of 2.55 and a debt-to-equity ratio of 2.77.
The company also recently disclosed a quarterly dividend, which will be paid on Friday, June 1st. Shareholders of record on Friday, April 20th will be issued a dividend of $0.126 per share. This represents a $0.50 annualized dividend and a yield of 0.60%. The ex-dividend date of this dividend is Thursday, April 19th. Zoetis’s dividend payout ratio (DPR) is 28.57%.
A number of analysts have commented on the company. BMO Capital Markets set a $78.00 price objective on Zoetis and gave the stock a “hold” rating in a report on Thursday, February 15th. Piper Jaffray Companies set a $88.00 target price on Zoetis and gave the company a “buy” rating in a report on Friday, February 16th. Cantor Fitzgerald set a $85.00 target price on Zoetis and gave the company a “buy” rating in a report on Tuesday, January 2nd. UBS reaffirmed a “neutral” rating on shares of Zoetis in a report on Friday, November 24th. Finally, Stifel Nicolaus reaffirmed a “buy” rating and issued a $86.00 target price (up from $84.00) on shares of Zoetis in a report on Friday, February 16th. One analyst has rated the stock with a sell rating, six have given a hold rating and thirteen have issued a buy rating to the company’s stock. Zoetis has an average rating of “Buy” and a consensus target price of $79.72.
Several large investors have recently bought and sold shares of ZTS. Polen Capital Management LLC purchased a new stake in shares of Zoetis during the fourth quarter worth $285,967,000. Bessemer Group Inc. lifted its position in shares of Zoetis by 231,590.8% during the fourth quarter. Bessemer Group Inc. now owns 2,117,654 shares of the company’s stock worth $152,557,000 after acquiring an additional 2,116,740 shares in the last quarter. BlackRock Inc. lifted its position in shares of Zoetis by 3.8% during the fourth quarter. BlackRock Inc. now owns 38,485,542 shares of the company’s stock worth $2,772,498,000 after acquiring an additional 1,394,156 shares in the last quarter. Millennium Management LLC lifted its position in shares of Zoetis by 208.1% during the fourth quarter. Millennium Management LLC now owns 1,984,470 shares of the company’s stock worth $142,961,000 after acquiring an additional 1,340,378 shares in the last quarter. Finally, Acadian Asset Management LLC lifted its position in shares of Zoetis by 111.3% during the fourth quarter. Acadian Asset Management LLC now owns 1,709,352 shares of the company’s stock worth $123,143,000 after acquiring an additional 900,261 shares in the last quarter. Hedge funds and other institutional investors own 92.29% of the company’s stock.
Zoetis Company Profile
Zoetis Inc is engaged in the discovery, development, manufacture and commercialization of animal health medicines and vaccines, with a focus on both livestock and companion animals. The Company has a business, commercializing products across eight core species: cattle, swine, poultry, sheep and fish (collectively, livestock) and dogs, cats and horses (collectively, companion animals), and within five product categories: anti-infectives, vaccines, parasiticides, medicated feed additives and other pharmaceuticals.
Receive News & Ratings for Zoetis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis and related companies with MarketBeat.com's FREE daily email newsletter.